Anthony G. Viscogliosi
Chief Executive Officer
Anthony G. Viscogliosi has 23 years of experience as an accomplished founder, entrepreneur, CEO, board member, and has authored more than 6,000 pages of investment research on orthopedics. He was also the first Wall Street Orthopedic Investment Banker and has executed more than 170 orthopedic deals of every type as principal or agent, buyer and seller. Mr. Viscogliosi is a founder of Small Bone Innovations, Inc., where he currently serves as Chairman and Chief Executive Officer. He raised $42.2 million for Small Bone Innovations, Inc.
Mr. Viscogliosi co-founded Viscogliosi Bros., LLC, the leading merchant bank and venture capital firm focused on the musculoskeletal/orthopedics industry, in 1999. Mr. Viscogliosi is a founder of the leading multi product spine non-fusion private company, Paradigm Spine, LLC. Mr. Viscogliosi is also a founder of the leading Spine Arthroplasty company, Spine Solutions, Inc.; financial founder of the leading Nucleus Arthroplasty company RayMedica, Inc.; founder of the leading reprocessor of single use disposable devices in the USA, Ascent Healthcare Solutions, Inc.; board member of SpineNext in its sale to Abbott. In addition, Mr. Viscogliosi is the co-founder of Musculoskeletal Clinical & Regulatory Advisers, LLC, orthopedic clinical, regulatory, IP and Reimbursement Consulting firm; and a founder and Partner in 6 orthopedic focused venture capital & private equity funds, as well as the only orthopedic focused hedge fund. In addition, he is a founder of the NYU-HJD Viscogliosi Bros. Spine Center. Mr. Viscogliosi received his B.S. in Economics from the University of Michigan in 1984. Prior to co-founding Viscogliosi Bros., he served with several regional brokerage and investment banking firms, as a Senior Vice President and Director of Medical Technology, Co-Director of Research, Assistant Director of Research and as an Equity Research Analyst.
Chief Operating Officer
Daniel has over 25 years experience in the medical device industry. Prior to joining Aperion in 2008, Daniel was responsible for the TRUREPAIR business unit at Smith & Nephew Endoscopy (SNE). Prior to Smith & Nephew, Daniel was responsible for global marketing activities at OsteoBiologics, Inc. (OBI) which provided the only off-the-shelf bioabsorbable implant for articular cartilage repair in Europe. OBI was acquired by Smith & Nephew in 2006. Prior to joining OBI, Daniel was the Director of Marketing for Regeneration Technologies, Inc (RTI), a leading allograft tissue processor for orthopaedic, spinal, craniofacial, and urologic surgical applications which went public in 2000. While at RTI, Daniel played a key role in creating and establishing RTI’s Sports Medicine business unit. Prior to joining RTI, he was the Director of the Sports Medicine Research and Development group at Surgical Dynamics, a subsidiary of U.S. Surgical Corporation. Much of his experience at U.S. Surgical focused on using resorbable materials for orthopaedic products. He is a member of the Society for Biomaterials and the American Association of Tissue Banks (AATB) where he holds a Certified Tissue Bank Specialist (CTBS) certification. He currently holds thirteen patents on implants and instruments used in orthopaedic and general surgery. Daniel received his Master of Science in Biomedical Engineering from the University of Alabama at Birmingham and his Bachelor of Science degree in Materials Science and Engineering from the Johns Hopkins University.
Chief Financial Officer
Mr. Cocke has served as our Chief Financial Officer since September 2008. Since 1997, Mr. Cocke has served as General Manager of NuPak Medical, Ltd., an ISO 13485-certified contract manufacturing medical device company. He is responsible for all aspects of management, including sales, finance and operations. Prior to that, from November 1993 to May 1996, Mr. Cocke was Chief Financial Officer of NuTech, Inc., a technology incubator subsidiary for KCI, a leader in tissue-based products for surgical procedures and wound healing. From 1991 to 1993, he was Director at the Corporate Development department at KCI. Prior to KCI, David was employed by GE Capital in its Corporate Finance Group and Salomon Brothers Inc in its Investment Banking Group. Mr. Cocke holds an MBA from the University of Virginia’s Darden Graduate School of Business Administration and a BBA with High Honors from the University of Texas at Austin.
Vice President, Quality Systems
Lance has over 20 years experience in FDA Requirements and Quality Systems. Prior to joining Aperion Biologics in November 2010, Lance was the Quality Manager at Zimmer Spine. Prior to Zimmer Spine, Lance was the Quality Engineering Manager for Abbott Spine working specifically with new product development teams. In addition to his industry experience, he spent 16 years as an investigator with the FDA. Lance specialized in medical device compliance and worked in both the San Francisco and Dallas districts. He spent 12 years as the resident in charge of the Austin field office and as contributor to the FDA international cadre. During his FDA career he audited medical device firms in the US, Europe and Canada. Lance received his Medical Device Level II certification in 1998 and received his Level II Auditor certification in 2003. Lance trained and certified FDA, Texas, and BSI auditors during his career with the FDA. Lance received his Bachelor of Science degree in Biotechnology from Oklahoma State University.
Board of Directors
David W. Anderson
Mr. Anderson is the Chairman and Chief Executive Officer of Orteq Ltd., an orthopedic medical device company focused on sports medicine. He also serves as Chairman of the Board of Gentis, Inc. a clinical stage spinal implant company which he joined in 2004. From 1999 to 2004, he was the founder and a director of Replication Medical, Inc., an orthopedic medical device company focused on spine surgeries. From 1994 to 1999, he served as the Chief Executive Officer of Bionx Implants, Inc., a leading manufacturer and marketer of reinforced polymer implants. From 1986 to 1989, he was the founder and Executive Vice President of Osteotech, Inc, a global leader in providing biologic solutions for regenerative medicine, which was acquired by Medtronic Inc. in 2010. Mr. Anderson also served as the Chief Executive Officer of Kensey Nash Corporation, a medical device company, from 1992 to 1994, and Sterilox Technologies, a manufacturer of non-toxic disinfectants, from 2000 to 2004. Mr. Anderson holds a B.S. in Chemical Engineering from Cornell University. Mr. Anderson brings to the Board over 25 years of experiences in entrepreneurship, strategic transactions and financing in the medical device industry.
France Dixon Helfer
Ms. Helfer is currently the President and Chief Executive Officer of TinyKicks LLC, a University of California healthcare technology company based in Irvine, California, since January 2015. From September 2011 to September 2014, Ms. Helfer was the President, Chief Executive Officer and Director of Halo Healthcare Inc. a medical device and diagnostics company focused on the detection and screening of breast cancer. Prior to that, from August 2004 to January 2008, Ms. Helfer was the President and Founder of Pegasus Biologics, Inc., which was acquired by Baxter Healthcare Inc. Prior to that. Ms. Helfer held a number of executive positions at various biotechnology companies,including Medtronics, Xenotech Labs, SORIN Bimedica, Eclipse Surgical and MMDDataDirect. Ms. Helfer serves on the boards of various business organizations and academic institutions, including Chapman University’s Crean College of Health and Behavioral Sciences. Ms. Helfer holds a B.A. in Biologic Sciences from California State University, Fullerton. Ms. Helfer brings to the Board over 20 years of experiences as a senior level executive in the medical device industry.
Alfred G. Holcomb
Mr. Holcomb is the Vice President of Acquisition and Divestutures at Lewis Energy Corp., an oil drilling company, since 2004, where he led the completion of numerous strategic transactions. From 1978 to 2004, Mr. Holcom was a partner at the law firm of Schoenbum, Curphy & Scanlan. Mr. Holcomb has been an active speaker on the Eagle Ford in conferences around the worldMr. Holcomb holds his B.A. in Finance in from University of Texas, a J.D. from St. Mary's University School of Law and a LL.M. in Taxation from New York University. Mr. Holcomb brings to the Board extensive experience and knowledge on strategic, legal and financial matters.
Kevin R. Stone
Dr. Stone is the founding scientist of our company and served as our Chief Executive Officer from 1996 to 2008, as a director since our inception and as our Chairman of the Board since 2014. Dr. Stone is a renowned orthopaedic surgeon and founded the Stone Clinic in 1988, an orthopedic clinic focused on biologic approaches to treating joint injuries. He is also the Founder and Chairman of Stone Research Foundation, an independent research institution investigating new techniques for joint health, arthritis and human performance, since 1996. Dr. Stone is the managing member of CrossCart, Inc., our controlling stockholder. Dr. Stone is also an attending staff at the California Pacific Medical Center and the San Francisco Surgery Center. From 1999 to 2003, Dr. Stone served as the Chief Executive Officer and Chairman of the Board of Joint Juice, Inc. (now Premier Nutrition Inc.). Dr. Stone is also the founder and Chief Executive Officer of Rescue Reel, LLC since 2006 and the founder of ProprioSense Holdings, LLC since 2012. Dr. Stone holds an A.B. cum laude in biology from Harvard College and an M.D. from the University of North Carolina School of Medicine. Dr. Stone is recognized internationally as a leading expert and authority of advanced orthopedic surgical and rehabilitation techniques to repair damaged cartilage and ligaments. He brings to the Board extensive expertise, knowledge and experience in the field of orthobiologic medicine and provides us with significant management, operational and financial support.
Mr. Ward has been our director since March 2014. Mr. Ward is the Vice President, Corporate Development at BioNano Genomics, Inc., a genomic mapping company. Prior to joining BioNano Genomics, Inc., from 2009 to 2013, Mr. Ward was a Vice President at Lurie Investment Fund, LLC, the venture capital arm of Ann and Robert H. Lurie Foundation, where he was he was responsible for managing the life sciences venture capital and private equity investments of the foundation. Prior to 2009, Mr. Ward worked for more than 15 years in the investment banking industries, holding various positions at Leerink Partners, Credit Suisse, Dresdner Kleinwort Wasserstein, BMO and Vector Securities. Mr. Ward holds a B.S. in finance from the University of Illinois. Mr. Ward brings to the Board over 20 years of life-sciences dedicated investment banking, venture capital and private equity experiences.